Optimal Antithrombotic Strategy After Transcatheter Aortic Valve Replacement: Is the "Less Is More" Concept Always Better?

Euihong Ko, Duk-Woo Park, Euihong Ko, Duk-Woo Park

No abstract available

Keywords: Editorials; antiplatelet agent; aortic stenosis; transcatheter aortic valve implantation.

Conflict of interest statement

None.

Figures

Figure 1. Main randomized clinical trials evaluating…
Figure 1. Main randomized clinical trials evaluating antithrombotic strategy after transcatheter aortic valve replacement.
ADAPT‐TAVR indicates Anticoagulation Versus Dual Antiplatelet Therapy for Prevention of Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement; APT, antiplatelet therapy; ASA, acetylsalicylic acid; ATLANTIS, Anti‐Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans‐Aortic Valve Implantation for Aortic Stenosis; AUREA, Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI; AVATAR, Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions; DAPT, dual antiplatelet therapy; ENVISAGE‐TAVR AF, The EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation–Atrial Fibrillation; GALILEO, Global Study Comparing a Rivaroxaban‐Based Antithrombotic Strategy to an Antiplatelet‐Based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes; LRT, Low Risk Transcatheter Aortic Valve Replacement; NOAC, Non‐vitamin K Antagonist Oral Anticoagulants; POPULAR‐TAVR, Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic‐Valve Implantation; SAPT, single antiplatelet therapy; and VKA, vitamin K antagonist.

References

    1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez‐Sarano M. Burden of valvular heart diseases: a population‐based study. Lancet. 2006;368:1005–1011. DOI: 10.1016/S0140-6736(06)69208-8.
    1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695–1705. DOI: 10.1056/NEJMoa1814052.
    1. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, et al. Transcatheter aortic‐valve replacement with a self‐expanding valve in low‐risk patients. N Engl J Med. 2019;380:1706–1715. DOI: 10.1056/NEJMoa1816885.
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2017;135:e1159–e1195. DOI: 10.1161/CIR.0000000000000503.
    1. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791. DOI: 10.1093/eurheartj/ehx391.
    1. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–2024. DOI: 10.1056/NEJMoa1509233.
    1. Chakravarty T, Søndergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, Jilaihawi H, Shiota T, Abramowitz Y, Jørgensen TH, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–2392. DOI: 10.1016/S0140-6736(17)30757-2.
    1. Muntané‐Carol G, Urena M, Munoz‐Garcia A, Padrón R, Gutiérrez E, Regueiro A, Serra V, Capretti G, Himbert D, Moris C, et al. Late cerebrovascular events following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13:872–881. DOI: 10.1016/j.jcin.2019.11.022.
    1. Rodés‐Cabau J, Masson J‐B, Welsh RC, Garcia del Blanco B, Pelletier M, Webb JG, Al‐Qoofi F, Généreux P, Maluenda G, Thoenes M, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon‐expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–1365. DOI: 10.1016/j.jcin.2017.04.014.
    1. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, Möllmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, et al. A controlled trial of rivaroxaban after transcatheter aortic‐valve replacement. N Engl J Med. 2020;382:120–129. DOI: 10.1056/NEJMoa1911425.
    1. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini AS, Veien KT, Abdel‐Wahab M, Kim WK, et al. Reduced leaflet motion after transcatheter aortic‐valve replacement. N Engl J Med. 2020;382:130–139. DOI: 10.1056/NEJMoa1911426.
    1. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, et al. Aspirin with or without clopidogrel after transcatheter aortic‐valve implantation. N Engl J Med. 2020;383:1447–1457. DOI: 10.1056/NEJMoa2017815.
    1. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, et al. Anticoagulation with or without clopidogrel after transcatheter aortic‐valve implantation. N Engl J Med. 2020;382:1696–1707. DOI: 10.1056/NEJMoa1915152.
    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923.
    1. Kuno T, Yokoyama Y, Briasoulis A, Mori M, Iwagami M, Ando T, Takagi H, Bangalore S. Duration of antiplatelet therapy following transcatheter aortic valve replacement: systematic review and network meta‐analysis. J Am Heart Assoc. 2021;10:e019490. DOI: 10.1161/JAHA.120.019490.
    1. Guedeney P, Mehran R, Collet JP, Claessen BE, Ten Berg J, Dangas GD. Antithrombotic therapy after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2019;12:e007411. DOI: 10.1161/CIRCINTERVENTIONS.118.007411.
    1. Steg PG, Bhatt DL. Is there really a benefit to net clinical benefit in testing antithrombotics? Circulation. 2018;137:1429–1431. DOI: 10.1161/CIRCULATIONAHA.117.033442.
    1. Makkar RR, Blanke P, Leipsic J, Thourani V, Chakravarty T, Brown D, Trento A, Guyton R, Babaliaros V, Williams M, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75:3003–3015. DOI: 10.1016/j.jacc.2020.04.043.
    1. Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, Alu MC, Madhavan MV, Chau KH, Russo M, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77:1149–1161. DOI: 10.1016/j.jacc.2020.12.052.
    1. Park H, Kang DY, Ahn JM, Kim KW, Wong AYT, Lam SCC, Yin WH, Wei J, Lee YT, Kao HL, et al. Rationale and design of the ADAPT‐TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement. BMJ Open. 2021;11:e042587. DOI: 10.1136/bmjopen-2020-042587.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere